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ABSTRACT
Objectives: It is unclear if morphology impacts on
diastole in hypertrophic cardiomyopathy (HCM). We
sought to determine the relationship between various
parameters of diastolic function and morphology in a
large HCM cohort.
Setting: Tertiary referral centre from Stanford,
California, USA.
Partecipants: 383 patients with HCM and normal
systolic function between 1999 and 2011. A group of
100 prospectively recruited age-matched and sex-
matched healthy participants were used as controls.
Primary and secondary outcome measures:
Echocardiograms were assessed by two blinded board-
certified cardiologists. HCM morphology was classified
as described in the literature (reverse, sigmoid,
symmetric, apical and undefined).
Results: Reverse curvature morphology was most
commonly observed (218 (57%). Lateral mitral annular
E′<12 cm/s was present in 86% of reverse, 88% of
sigmoid, 79% of symmetric, 86% of apical and 81% of
undefined morphology, p=0.65. E/E′ was similarly
elevated (E/E′: 12.3±7.9 in reverse curvature, 12.1±6.1
in sigmoid, 12.7±9.5 in symmetric, 9.4±4.0 in apical,
12.7±7.9 in undefined morphology, p=0.71) and
indexed left atrial volume (LAVi)>40 mL/m2 was
present in 47% in reverse curvature, 33% in sigmoid,
32% in symmetric, 37% in apical and 32% in
undefined, p=0.09. Each morphology showed altered
parameters of diastolic function when compared with
the control population. Left ventricular (LV) obstruction
was independently associated with all three diastolic
parameters considered, in particular with LAVi>40 mL/
m2 (OR 2.04 (95% CI 1.23 to 3.39), p=0.005), E/E′>15
(OR 4.66 (95% CI 2.51 to 8.64), p<0.001) and E′<8
(OR 2.55 (95% CI 1.42 to 4.53), p=0.001). Other
correlates of diastolic dysfunction were age, LV wall
thickness and moderate-to-severe mitral regurgitation.
Conclusions: In HCM, diastolic dysfunction is present
to similar degrees independently from the
morphological pattern. The main correlates of diastolic
dysfunction are LV obstruction, age, degree of
hypertrophy and degree of mitral regurgitation.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is an
inherited cardiomyopathy characterised by
hypertrophy, ﬁbrosis and ﬁbre disarray.1
One of the main pathophysiological fea-
tures of HCM is diastolic dysfunction. The
presence of subtle changes in left ventricular
(LV) ﬁlling may even identify patients with
preclinical disease.2 Interventions such as
medical therapy, alcohol septal ablation and
surgical myectomy improve symptoms by
reducing the LV outﬂow tract gradients.3
Various morphological categories have
traditionally been used to describe the
appearance of the hypertrophic LV and
these include: reverse curvature, sigmoid
curvature, symmetric (sometimes referred to
as concentric) and apical.
The question of whether different mor-
phological subtypes of HCM (which often
portend different therapies) are associated
with different degrees of diastolic dysfunc-
tion is unknown. We hypothesise that the
degree of diastolic dysfunction is poorly
related to morphology and that it is present
despite the presence of a different
Strengths and limitations of this study
▪ Large population considered, with complete
echocardiographic assessment and a subgroup
with genotype characterisation.
▪ First study to consider diastology and relation
with morphology.
▪ Thorough analysis of what are the major deter-
minants of diastolic dysfunction in hypertrophic
cardiomyopathy.
▪ Patients not studied with cardiac MR.
▪ Diastole not studied with pulmonary flow in all
patients.
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distribution of hypertrophy. Besides, we sought to
analyse the echocardiographic correlates of diastolic
dysfunction.
METHODS
Study population
From January 1999 to November 2011, 410 adult (age
18–91 years) consecutive patients diagnosed with HCM
were enrolled in the Stanford Inherited Cardiomyopathy
Registry. For the present study, we retrospectively
selected and analysed patients with HCM with preserved
LV systolic function (n=383, LV ejection fraction (LVEF)
>55%). Twenty-seven patients with LV systolic dysfunc-
tion and/or with permanent atrial ﬁbrillation at enrol-
ment were excluded from the study.
The diagnosis of HCM was based on the presence of
signiﬁcant LV hypertrophy (end-diastolic wall thickness
≥15 mm at M-mode or two-dimensional (2D) echocardi-
ography) in the absence of other aetiologies (according
to international criteria) or wall thickness between 13
and 15 mm, in the presence of an abnormal ECG or
familial history of inherited cardiomyopathies.1 Patients
were medically treated with β-blockers, calcium channel
blockers, antiarrhythmics and diuretics, as clinically indi-
cated. Implantable cardioverter-deﬁbrillators were uti-
lised for primary or secondary prevention of sudden
cardiac death.
Genetic testing assessed eight HCM-associated
myoﬁlament-encoding genes involving myosin-binding
protein C (MYBPC3), β-myosin heavy chain (MYH7),
essential and regulatory myosin light chains (MYL2,
MYL3), cardiac troponin T (TNNT2), cardiac troponin I
(TNNI3), α-tropomyosin (TPM1) and cardiac actin
(ACTC), as well as three genes associated with metabolic
cardiomyopathies: α-galactosidase (GLA) for Fabry’s
disease, LAMP2 for Danon’s disease and PRKAG2 for
PRKAG2 cardiomyopathy.
Written informed consent was obtained using a proto-
col approved by the Stanford Institutional Review Board.
The investigation is in compliance with the principles
outlined in the Declaration of Helsinki,4 state and
national law and was approved by the Institutional
Review Board at Stanford.
Controls
The control population included 100 prospectively
recruited age-matched and gender-matched participants.
A comprehensive health questionnaire was administered
to these patients to exclude any symptoms suggestive of
cardiovascular disease. We excluded subjects who had a
family history of dilated cardiomyopathy or coronary
artery disease in relatives younger than 55 years of age.
Echocardiographic and Doppler studies
Echocardiographic images were acquired on Philips
IE 33 or HP 5500 (Andover, Massachusetts, USA)
depending on the period of enrolment. Based on
echocardiography, ventricular morphology was classiﬁed
in various subgroups. Group 1: reverse curvature
deﬁned as a predominant mid-septal convexity towards
the LV cavity, with the cavity itself having an overall cres-
cent shape; group 2: hypertrophied with a proximal
septal bulge (sigmoid); group 3: hypertrophied with a
normal shape (symmetric); group 4: apical deﬁned as a
predominant apical distribution of hypertrophy (in the
absence of signiﬁcant hypertrophy among other LV seg-
ments); group 5: undeﬁned if the morphology did not
conform to one of the four deﬁned subgroups and if an
overall straight or variable convexity that was neither pre-
dominantly convex nor concave towards the LV cavity
was present.5
Using M-mode and 2D, we measured the LV diameter,
the thickness of the interventricular septum (IVS) and
the LV posterior wall, as well as the left atrial (LA) end-
systolic diameter according with the recommendations of
the American Society of Echocardiography (ASE).6 The
LVEF was assessed between the apical four-chamber and
two-chamber view, using the biplane method of discs.7
The systolic intraventricular gradient was quantiﬁed
using the continuous-Doppler technique. A peak gradi-
ent >30 mm Hg at rest was considered signiﬁcant.8
Mitral regurgitation (MR) severity was assessed accord-
ing to the ASE guidelines.9 LV ﬁlling was assessed by
pulsed Doppler at the level of the mitral opening tips.
The pattern of LV ﬁlling was classiﬁed as the restrictive
ﬁlling pattern in the presence of E-deceleration time
<120 ms or of E/A wave ≥2 associated with
E-deceleration time ≤150 ms, abnormal relaxation: E/A
<1 associated with E-deceleration time >220 ms or
normal (or ‘pseudonormal’): intermediate ﬁlling
pattern.10
We measured peak myocardial early diastolic velocity
at the lateral mitral annulus (lateral E′) and transmitral
to tissue Doppler imaging (TDI) early diastolic velocity
ratio (E/E′; using tissue Doppler imaging).11
The LA and right atrial (RA) volumes were measured
in systole just before the mitral valve opening, using a
monoplane area-length method.12
According to the ASE guidelines, diastolic dysfunction
was deﬁned in the presence of severe LA dilation
indexed left atrial LA volume (LAVi)>40 mL/m2),
increased E/E′ (>15), reduced E′ (<8 cm/s) and a
restrictive pattern.13
Tricuspid annular plane systolic excursion (TAPSE)
was measured from the systolic excursion of the tricus-
pid lateral annulus using a 2D methodology. According
to the ASE guidelines, RV systolic dysfunction is consid-
ered in the presence of a TAPSE <16 mm or a fractional
area change (apical four-chamber view) <35%.14 The
RA area was measured in systole just before the tricuspid
valve opening.
Statistical analysis
Results are expressed as mean±SD for continuous vari-
ables or as the number of cases and percentage for
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categorical variables. Comparison of groups was per-
formed using Student’s t test for continuous variables
with correction for unequal variance when necessary
and χ2 test or Fisher’s exact test, as appropriate for cat-
egorical variables. Comparisons between continuous
variables among multiple groups were performed by
analysis of variance—using the Brown–Forsythe statistic
when the assumption of equal variances did not
hold—while the proportions were compared by means
of the χ2 test, using Fisher’s exact test when necessary.
To analyse the echocardiographic correlates of LV dia-
stolic dysfunction, we considered the total population
excluding the 16 patients with apical HCM (AHCM).
Logistic regression analysis was used to determine the
factors independently associated with LA dilation, reduced
E′, increased E/E′ and restrictive pattern. The ﬁrst analysis
considered the whole population while the second analysis
included the subgroup of 166 patients with a genotype. To
determine intrareader and inter-reader variability, the
studies were read by two blinded investigators. A random
sample of 25 studies was chosen to calculate the intrarea-
der and inter-reader variability. Intrareader and inter-
reader variability was quantiﬁed using mean differences as
well as the intraclass correlation coefﬁcient and no signiﬁ-
cant difference (p=0.81) between the two readers was
observed. Statistical analysis was performed using the
PASW software (PASW 18.0 Inc, Chicago, Illinois, USA).
Table 2 Characteristics of patient population in comparison with controls
Total HCM (n=383) Controls (n=100) p Value
Clinical and demographic
Age (years) 51±16 52±16 NS
Male sex, n (%) 227(59) 62(62) NS
Echocardiography
IVS (mm) 17.7±5.1 7.4±1.2 <0.001
PW (mm) 12.1±3.1 7.4±1.1 <0.001
LVEF (%) 69±8 65±6 NS
E wave velocity (cm/s) 83±27 65±14 <0.001
A wave (cm/s) 73±30 57±20 <0.001
E/A 1.32±0.6 1.27±0.5 NS
Deceleration time (ms) 210±63 196±46 NS
Restrictive filling pattern, n (%) 14(4) 0(0) 0.006
E′ 8.14±3.39 11.9±4.8 <0.001
A′ 7.71±3.0 9.2±2.4 <0.001
E/E′ 12.31±7.91 5.96±2.13 <0.001
LAVi (mL/m2) 39.9±18.7 26.3±19.1 <0.001
Moderate-to-severe MR, n (%) 24(6) 0(0) 0.01
Indexed RVEDA (cm2/m2) 8.8±2.4 9.9±2.3 NS
RVFAC (%) 49±8 48±7 NS
TAPSE<16 mm, n (%) 15(3) 0(0) <0.001
RV dysfunction*, n (%) 17(4) 0(0) <0.001
RAVi (mL/m2) 21.7±8.9 21.6±9.4 NS
RVSP mm Hg 32±11 19±7 <0.001
*Defined as RVFAC<33% and/or TAPSE<16 mm.
EF, ejection fraction; ICD, implantable cardioverter defibrillator; HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; LAVi, left
atrium volume index; LV, left ventricle; LVEF, left ventricle ejection fraction, MR, mitral regurgitation; PW, posterior wall; RAVi, right atrium
volume index; RV, right ventricle; RVEDA, right ventricular end-diastolic area; RVFAC, right ventricular fractional area change; RVSP, right
ventricle systolic pressure; TAPSE, tricuspid annular plane systolic excursion.
Table 1 Main baseline characteristics of HCM population
Total (n=383)
Clinical and demographic
Age (years) 51±16
Male sex, n (%) 254 (59)
NYHA III-IV, n (%) 56 (15)
Echocardiography
IVS (mm) 17.7±5.1
PW (mm) 12.1±3.1
RWT 0.74±0.2
LVEF (%) 69±8
Resting LV gradient >30 mm Hg, n (%) 138 (35)
Restrictive filling pattern, n (%) 14 (4)
Moderate-to-severe MR, n (%) 24 (6)
Medications
Beta-blockers, n (%) 218 (52)
Calcium channel blockers, n (%) 86 (21)
ACE inhibitors, n (%) 65 (16)
Diuretics, n (%) 50 (13)
Antiarrhythmic therapy, n (%) 17 (5)
ICD, n (%) 120 (31)
ACE, angiotensin converting enzyme; EF, ejection fraction; HCM,
hypertrophic cardiomyopathy; ICD, implantable cardioverter
defibrillator; IVS, interventricular septum; LAVi, left atrium volume
index; LV, left ventricle; LVEF, left ventricle ejection fraction; MR,
mitral regurgitation; PW, posterior wall; RAVi, right atrium volume
index; RV, right ventricle; RVSP, right ventricle systolic pressure;
RWT, relative wall thickness.
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RESULTS
Patient characteristics
The main baseline characteristics of the study popula-
tion are summarised in table 1. Mean age at the initial
evaluation was 51±16 years; 254 patients (59%) were
male, 56 (15%) were symptomatic (NYHA III-IV) and
134 (35%) had a signiﬁcant rest LV gradient (either at
the LVOT or mid-ventricular gradient). Eighty-four
(48%) patients had a known disease-related mutation,
with a prevalence in MYH7 (n:40, 47%). Patients were
treated mainly with β-blockers (52%) and calcium
channel-blockers (21%). A known ischaemic heart
disease was present in 5% of cases.
Diastolic parameters compared with the control population
Diastole was impaired in the overall HCM population as
compared with the healthy control subjects (table 2).
Compared with controls, patients with HCM showed a
greater left atrial size (LAVi; 39.9±18.7 vs 26.3±19.1,
p<0.001), higher E/E′ (12.31±7.91 vs 5.96±2.13, p<0.001)
and signiﬁcantly lower E′ values (8.14±3.39 vs 11.9±4.8,
p<0.001). A restrictive pattern was present in 14 patients
with HCM (4%), while it was absent in the control
population.
General features of patients divided by morphology
Table 3 represents the clinical and echocardiographic
measurements categorised by morphology. In total 218
(57%) patients comprised group 1, while 27 (7%), 69
(18%), 16 (4%) and 53 (14%) patients belonged to
groups 2, 3, 4 and 5, respectively.
There was no signiﬁcant difference in age at enrol-
ment among the ﬁve groups, though patients with septal
sigmoid morphology were slightly older (50±17, 58±14,
49±18, 52±14, 50±14 in groups 1, 2, 3, 4 and 5, respect-
ively, p=0.13). Patients with reverse morphology were
characterised by a more severe IVS hypertrophy (19.7
±5.2, 16.2±3.3, 14.9±4.1, 12.6±2.1, 15.4±3.4 in groups 1,
2, 3, 4 and 5, respectively, p<0.001).
Diastolic parameters in subgroups with different
morphology
Diastole was similarly affected in each morphology sub-
group (table 3). A restrictive pattern was rarely observed
(3% vs 0% vs 5% vs 6% vs 6% in groups 1, 2, 3, 4 and 5,
respectively, p=0.53). There was no difference in the E′
and E/E′ ratio values between the HCM subgroups (E′
7.9±3.3 in group 1, 8.1±2.6 in group 2, 8.4±3.7 in group
3, 8.7±3.5 in group 4, 8.3±3.7 in group 5, p=0.82; E/E′:
Table 3 Characteristics of the patient population according to different morphology
Group 1
(n=218)
Group 2
(n=27)
Group 3
(n=69)
Group 4
(n=16)
Group 5
(n=53) p Value
Clinical and demographic
Age (years) 50±17 58±14 49±18 52±14 51±14 0.13
Male sex, n (%) 126 (56) 21 (81) 37 (54) 11 (72) 32 (57) 0.24
NYHA III-IV, n (%) 28 (13) 0 (0) 7 (10) 2 (13) 8 (15) 0.33
Genotype on 173 patients, n (%) 53 (55) 5 (38) 12 (39) 2 (29) 12 (48) 0.37
Echocardiography
IVS (mm) 19.7±5.2 16.2±3.3 14.9±4.1 12.6±2.1 15.4±3.4 <0.001*
PW (mm) 11.9±2.9 11.4±2.0 13.8±3.4 10.7±2.5 11.2±2.4 <0.001*
LVEF (%) 70±7 69±6 68±9 66±6 69±9 0.19
LV gradient >30 mm Hg, n (%) 87 (40) 8 (30) 17 (25) 3 (19) 19 (36) 0.010†
E wave (cm/s) 82±26 88±28 85±27 70±12 91±31 0.07†
E/A 1.3±0.59 1.1±0.46 1.33±0.62 1.5±0.55 1.22±0.63 0.19
E/A>2, n (%) 21 (10) 1 (4) 9 (15) 3 (19) 3 (6) 0.34
Deceleration time (ms) 212±62 213±47 207±77 166±34 213±64 0.09
Restrictive pattern (n, %) 7 (3) 0 (0) 4 (5) 1 (6) 3 (6) 0.53‡
E′ (cm/s) 7.9±3.3 8.1±2.6 8.4±3.7 8.7±3.5 8.3±3.7 0.82*
E′<12 cm/s (n, %) 160 (86) 23 (88) 44 (79) 12 (86) 39 (81) 0.65*
E/E′ 12.3±7.9 12.1±6.1 12.7±9.5 9.4±4.0 12.7±7.9 0.71*
LAVi mL/m2 42.4±19.1 36.2±10.5 34.7±14.7 38.6±13.6 39.1±24.5 0.03*
LAVi>40 mL/m2, n (%) 102 (47) 9 (33) 22 (32) 6 (37) 17 (32) 0.09*
Moderate-to-severe MR 15 (7) 2 (7) 3 (4) 1 (6) 3 (6) 0.96‡
RV dysfunction, n (%) 11 (5) 0 (0) 3 (0) 0 (0) 3 (6) 0.19‡
RVSP mm Hg 33±11 28±7 30±9 35±11 30±9 0.2*
RAVi (mL/m2) 21.7±8.9 23.8±9.9 20.4±9.3 23.6±8.8 22.1±7.6 0.43
Group 1: septal reverse; group 2: septal sigmoid; group 3: symmetric; group 4: apical; group 5: undefined.
p Value indicates the difference between subgroups according to morphology.
*All the morphology subgroups are significantly different (p<0.05) in comparison with controls.
†Four morphology subgroups are significantly different (p<0.05) in comparison with controls.
‡Three morphology subgroups are significantly different (p<0.05) in comparison with controls.
IVS, interventricular septum; LAVi, left atrium volume index; LV, left ventricle; LVEF, left ventricle ejection fraction, MR, mitral regurgitation;
PW, posterior wall; RAVi, right atrium volume index; RV, right ventricle; RVSP, right ventricle systolic pressure.
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12.3±7.9, 12.1±6.1, 12.7±9.5, 9.4±4.0, 12.7±7.9 in groups
1, 2, 3, 4 and 5, respectively, p=0.71; ﬁgure 1). Patients
with reverse curvature morphology showed more severe
LA dilation in comparison to patients with sigmoid
morphology (LAVi 42.4±19.1, 36.2±10.5, 34.7±14.7, 38.6
±13.6, 39.1±24.5 mL/m2 in groups 1, 2, 3, 4 and 5,
respectively, p=0.03). We compared the diastolic para-
meters of each HCM subgroup with those of the control
population. E′, E/E′ ratio and LAVi were different in
each studied group compared with controls (ﬁgure 2).
Right ventricular systolic pressure and relationship
with LV diastolic function
RVSP data were available on 222 patients (58%). RVSP
was higher in patients with LAVi>40 mL/m2 (34±11 vs 29
±9 mmHg, p=0.001), in patients with E′<8 (33±11 vs 30
±9, p=0.03) and in patients with E/E′>15 (35±13 vs 29±8,
p=0.003; ﬁgure 3).
Correlates of diastolic dysfunction
Table 4 illustrates the independent correlates of diastolic
dysfunction at multivariate analysis. LV gradient
>30 mmHg was associated with all three diastolic para-
meters considered (ﬁgure 4), in particular with
LAVi>40 mL/m2 (OR 2.04 (95% CI 1.23 to 3.39), p=0.005),
E/E′>15 (OR 4.66 (95% CI 2.51 to 8.64), p<0.001) and E′
<8 (OR 2.55 (95% CI 1.42 to 4.53), p=0.001). Also, age,
moderate to severe MR, indexed IVS thickness and relative
wall thickness (RWT) were associated with various diastolic
parameters (table 4).
The only independent correlate of restrictive ﬁlling
pattern was age (OR 0.94 (95% CI 0.91 to 0.98), p=0.001).
In order to analyse the possible contribution of the
presence of one or more mutations, we also considered
a model including the genotype (on 166 patients with
data available). The presence of a disease-causing muta-
tion was independently associated only with E′<8 (OR
2.52 (95% CI 1.14 to 5.57), p=0.02).
DISCUSSION
Our study has two main ﬁndings. The ﬁrst is that dia-
stolic dysfunction equally affects patients with HCM
even in the presence of a different distribution of
hypertrophy. Each morphology subgroup compared
with the age-matched and sex-matched control popula-
tion was characterised by indicators of diastolic dysfunc-
tion of similar degree. The second is that diastolic
dysfunction in HCM is associated with various clinical
and echocardiographic variables as LV obstruction, age,
degree of MR and LV hypertrophy. In particular, LV
obstruction at rest was independently associated with all
the echocardiographic indicators of diastolic dysfunc-
tion studied.
Diastolic dysfunction is a large contributor to the
underlying pathophysiology in patients with HCM and it
is a major characteristic of the disease. Its precise nature
Figure 1 Two-dimensional images showing hypertrophic cardiomyopathy (HCM) morphological subtypes. Reverse curvature
(A); symmetric (B); apical (C); sigmoid (D); indefinite, in this case end-stage HCM (E).
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and aetiology are complex and may be affected by
several variables such as myocardial ischaemia, intracel-
lular calcium overload, myocardial ﬁbrosis and atrial
haemodynamics.1 15 In several studies, some degree of
impaired LV relaxation and reduced myocardial compli-
ance has been present in the vast majority of patients
with HCM and some studies have demonstrated that
these factors are associated with poor prognosis.16–18
The importance of diastolic dysfunction in HCM has led
to an extensive search for accurate, non-invasive
methods of quantifying severity, but no single non-
invasive measure has yet been validated.16
Diastolic dysfunction and morphology in HCM
The distribution of ventricular and septal wall thicken-
ing in HCM varies widely. Ventricular hypertrophy can
be focal or diffuse, asymmetrical or concentric, obstruct-
ive or non-obstructive. HCM can be classiﬁed into at
least ﬁve major anatomic subsets based on the septal
contour, as well as the location and extent of hyper-
trophy: reverse curvature, sigmoidal, symmetric, apical
and neutral contour. The most common HCM morph-
ology is reverse curvature and it is most associated with
identiﬁable HCM-associated gene mutations.5 One of
the more unusual hypertrophic morphologies is
AHCM.1 Although there are extensive investigations
regarding diastolic function in patients with HCM, few
studies have evaluated diastolic function according to
the morphological pattern.
Ha et al19 studied a cohort of 29 patients with apical
HCM. E′ was <0.10 m/s in all patients, while LA volume
was above normal in 83% of the patients, suggesting the
presence of chronic diastolic dysfunction. Elevated
ﬁlling pressure (based in E/E′) at rest was observed in
approximately 20% of patients.
In our population, diastolic dysfunction was equally
present in HCM characterised by different morphologies
(comparing each group with a sex-matched control
population). When myocardial relaxation is normal, E′
is usually ≥12 cm/s. In our study, E′ was <12 cm/s in the
majority of patients, despite the presence of different
morphologies, and E′ was signiﬁcantly lower in each sub-
group compared with the control population. Nagueh
et al20 reported that when the mitral E velocity was cor-
rected for the inﬂuence of myocardial relaxation (ie,
the E/E′ ratio), it correlated well with the mean pul-
monary capillary wedge pressure. Geske et al,21 in a
population of symptomatic patients with HCM, found
Figure 2 Diastolic dysfunction and RVSP in hypertrophic cardiomyopathy (HCM) population according to morphology and in
controls. p<0.001 between subgroups in HCM and controls for all the four variable considered; p=0.03 for LAVi between septal
reverse and symmetric; p = NS for all the other variables in HCM subgroups. The values are expressed as means ±2 SDs.
AHCM, apical hypertrophic cardiomyopathy; LAVi, left atrial indexed volume; RVSP, right ventricular systolic pressure.
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that Doppler echocardiographic estimates of LV ﬁlling
pressure with the use of transmitral ﬂows and mitral
annular velocities correlate modestly with direct meas-
urement of LAP at the catheterisation. In our cohort,
the E/E′ ratio was signiﬁcantly elevated in each morpho-
logy subgroup.
LA volume, a reliable mirror of elevated LV and LA
ﬁlling pressures in the absence of mitral valve disease, is
considered to be an independent prognostic marker in
patients with HCM.22 In our population, a LA severe
dilation (LAVi>40 mL/m2) was observed slightly more
frequently in septal reverse form, but it was equally
present in all the studied subgroups. It is striking that
diastolic dysfunction was found to be not signiﬁcantly
affected by distribution of hypertrophy in the series
studied. It could be hypothesised that morphologies dif-
ferent from reverse curvature forms (characterised by a
more diffuse LV hypertrophy and by a very common
presence of an identiﬁable HCM-associated mutation)
may be affected by a less severe diastolic dysfunction.
Our results argue against this hypothesis, underscoring
that diastolic function appears to be independent from
distribution of ventricular hypertrophy.
A parameter that did not emerge as signiﬁcantly dif-
ferent between patients with HCM and controls was the
E/A ratio. This is probably related to the fact that
patients with HCM can have a varied degree of diastolic
dysfunction with, in some cases, a severe increase of the
E/A ratio, but also an inverted diastolic transmitral
Doppler inﬂow pattern. This result underscores the role
of a multiparametric assessment of diastolic dysfunction.
Correlates of diastolic dysfunction
Diastolic dysfunction in HCM is complex and multifac-
torial, with changes at the molecular, myocardial tissue
and global LV levels.23 Studies considering the correlates
of diastolic dysfunction and focusing on echocardio-
graphic parameters are lacking. It is difﬁcult to establish
if diastolic function in HCM is a main phenotypic
expression, primarily related to a cellular and molecular
mechanisms of abnormal relaxation, or it is more
affected by a macroscopic subversion of the LV architec-
ture, with a small LV cavity and, in some cases, an
obstruction producing high intracavitary pressures. More
than 400 mutations have been described in HCM, which
result in the production of abnormal myocardial sarco-
meric proteins producing an alteration of contraction
and relaxation characteristics.24 These abnormalities
vary with the sarcomeric protein affected and the site
and effect of the mutation.25 Our study explored mainly
the macroscopic part of the problem, but what emerged
is that diastole is associated mainly with LV obstruction,
then with age, degree of MR and LV hypertrophy.
Figure 3 Right ventricular systolic pressure (RVSP) relationship with parameters of left ventricle (LV)diastolic dysfunction. The
values are expressed as ±2 SDs. (A) RVSP and LAVi; (B) RVSP and E′; (C) RVSP and E/E′; (D) Correlation between LAVi and RVSP.
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The presence of at least one gene mutation appears to
be independently related only to decreased E′, with no
independent association with other parameters of dia-
stolic dysfunction. Lower values of E′ at TDI have been
previously demonstrated to predict the genetic status.26
Future studies are needed to better understand the
distribution of genetic mutations according to different
morphology. Our study explored simply the role of
genetic status (mutation vs no mutation) in predicting
diastolic abnormalities, but it is possible that certain
disease-causing known mutations may have a direct role
at a microscopic level that generates an overall diastolic
Figure 4 Presence of obstruction at rest and diastolic dysfunction. The values are expressed as means±2 SDs. Left ventricle
(LV)>30 mm Hg: presence of LV obstruction at rest (LV gradient>30 mm Hg). (A) LV>30 mmHg and LAVi; (B) LV>30 mmHg
and E′; (C) LV>30 mmHg and E/E′; (D) LV>30 mmHg and RVSP.
Table 4 Multivariate regression for diastolic dysfunction in all patients excluding apical HCM
LA volume >40 mL/m2 E′<8 E/E′>15
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Multivariate analysis
Age (years) 1.05 (1.03 to 1.07) <0.001 1.04 (1.02 to 1.06) <0.001
Male sex
Indexed IVS (mm/m2) 1.42 (1.24 to 1.62) <0.001 1.17 (1.05–1.31) 0.006
RWT (per 0.3 units) 2.40 (1.58 to 3.64) <0.001
Moderate-to-severe MR 6.10 (1.8 to 19.80) 0.003 6.38 (1.45 to 28.19) 0.01
LV gradient >30 mm Hg 2.04 (1.23 to 3.39) 0.005 2.55 (1.42 to 4.53) 0.001 4.66 (2.51 to 8.64) <0.001
Model adding genotype*
Age (years) 1.05 (1.02 to 1.08) <0.001 1.05 (1.01 to 1.08) 0.005
Male sex 2.6 (1.65 to 3.82) 0.001 0.38 (0.15 to 0.96) 0.04
Indexed IVS (mm/m2) 1.50 (1.95 to 1.89) <0.001
RWT (per 0.3 units)
Moderate-to-severe MR 15.06 (1.7 to 130.55) 0.01 7.58 (1.89 to 30.2) 0.01
LV gradient >30 mm Hg 2.17 (1.01 to 4.76) 0.05 2.89 (1.26 to 6.64) 0.01 6.73 (2.67 to 19.61) <0.001
Gene mutation (s)* 2.52 (1.14 to 5.57) 0.02
*On 166 patients.
IVS, interventricular septum; LV, left ventricle, MR, mitral regurgitation; RWT, relative wall thickness.
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dysfunction. Also, in recent years, several studies ana-
lysed with new sequencing methods the genome of
patients affected by cardiomyopathies, and it is possible
that in the next few years growing evidence will generate
a better understanding of genotype/phenotype correla-
tions in HCM.
At this point, we consider these variables as correlates;
future multicentre studies are needed to validate these
ﬁndings.
Limitations
The study has some limitations. The analysis did not
include cardiac MR studies of the indexed mass (we also
did not use Devereux’ formula because it is inaccurate
in patients with asymmetrical HCM) because these data
were not available in the whole population. Thus, an
evaluation of the possible relationship between diastolic
function and cardiac mass was not possible. We did not
consider pulmonary ﬂow as a parameter to assess dia-
stolic function, because it was available in a minority of
patients.
The study was limited to clinical and echocardio-
graphic data. Thus, invasive haemodynamics and bio-
markers as brain natriuretic peptide (BNP) were
available only in a minority of patients and a systematic
comparison with cardiac catheterisation was not consid-
ered in the present study.
Generally, the variables considered to assess diastolic
function (and, in particular, E and A wave velocity at the
transmitral Doppler and E/E′ ratio) are to a certain
degree affected by loading conditions. Thus, E and E′
wave velocity may be higher in the presence of signiﬁ-
cant MR, due to an increased preload, and similarly,
these values could be affected by the use of diuretics. It
is thus in some way expected that signiﬁcant MR is asso-
ciated with LA enlargement and E/E′ ratio. However,
the presence of moderate-to-severe MR and the use of
diuretics (in the majority of the cases thiazides rather
than loop diuretics and at low dosages) were rare (6%
and 13%, respectively). Besides, from our multivariate
analysis, the other parameters considered (and, in par-
ticular, LV obstruction) were associated to diastolic dys-
function independently from MR.
The analysis is limited to the baseline; thus, prognostic
implications and insights about the evolution of diastolic
dysfunction during the follow-up cannot be inferred from
our study.
CONCLUSIONS
Diastolic dysfunction, identiﬁed by various 2D and
Doppler echocardiographic parameters, is prevalent in
patients with HCM. Diastolic dysfunction does not
appear to be strongly correlated with a particular mor-
phological pattern despite the different distribution of
LV hypertrophy. LV obstruction, age, degree of hyper-
trophy and MR are the main correlates of diastolic dys-
function. Future studies analysing genotype–phenotype
associations may be able to clarify the various molecular
mechanisms underlying diastolic dysfunction.
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